Correlation Between Johnson Johnson and POINT Biopharma
Can any of the company-specific risk be diversified away by investing in both Johnson Johnson and POINT Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Johnson Johnson and POINT Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Johnson Johnson and POINT Biopharma Global, you can compare the effects of market volatilities on Johnson Johnson and POINT Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Johnson Johnson with a short position of POINT Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Johnson Johnson and POINT Biopharma.
Diversification Opportunities for Johnson Johnson and POINT Biopharma
-0.34 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Johnson and POINT is -0.34. Overlapping area represents the amount of risk that can be diversified away by holding Johnson Johnson and POINT Biopharma Global in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on POINT Biopharma Global and Johnson Johnson is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Johnson Johnson are associated (or correlated) with POINT Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of POINT Biopharma Global has no effect on the direction of Johnson Johnson i.e., Johnson Johnson and POINT Biopharma go up and down completely randomly.
Pair Corralation between Johnson Johnson and POINT Biopharma
Considering the 90-day investment horizon Johnson Johnson is expected to under-perform the POINT Biopharma. But the stock apears to be less risky and, when comparing its historical volatility, Johnson Johnson is 3.02 times less risky than POINT Biopharma. The stock trades about -0.01 of its potential returns per unit of risk. The POINT Biopharma Global is currently generating about 0.08 of returns per unit of risk over similar time horizon. If you would invest 661.00 in POINT Biopharma Global on September 2, 2024 and sell it today you would earn a total of 245.00 from holding POINT Biopharma Global or generate 37.07% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 31.05% |
| Values | Daily Returns |
Johnson Johnson vs. POINT Biopharma Global
Performance |
| Timeline |
| Johnson Johnson |
| POINT Biopharma Global |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Johnson Johnson and POINT Biopharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Johnson Johnson and POINT Biopharma
The main advantage of trading using opposite Johnson Johnson and POINT Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Johnson Johnson position performs unexpectedly, POINT Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in POINT Biopharma will offset losses from the drop in POINT Biopharma's long position.| Johnson Johnson vs. Crinetics Pharmaceuticals | Johnson Johnson vs. Enanta Pharmaceuticals | Johnson Johnson vs. Amicus Therapeutics | Johnson Johnson vs. Connect Biopharma Holdings |
| POINT Biopharma vs. Oric Pharmaceuticals | POINT Biopharma vs. Lyra Therapeutics | POINT Biopharma vs. Inhibrx | POINT Biopharma vs. ESSA Pharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Complementary Tools
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |